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Abstract
Among diffuse gliomas, oligodendrogliomas show relatively better prognosis, respond well to radiotherapy and
chemotherapy, and seldom progress to very aggressive tumors. To elucidate the genetic and epigenetic
background for such behavior and tumor evolution during tumor relapse, we comparatively analyzed 12 pairs of
primary and recurrent oligodendrogliomas with 1p/19q-codeletion. Initial treatment for these patients was mostly
chemotherapy alone. Temozolomide was used for 3, and procarbazine, nimustine and vincristine (PAV chemotherapy)
were used for 7 patients. World Health Organization histological grade at recurrence was mostly stable; it was increased
in 2, the same in 9, and decreased in 1 cases. Whole-exome sequencing demonstrated that the rate of shared mutation
between the primary and recurrent tumors was relatively low, ranging from 3.2-57.9% (average, 33.3%), indicating a
branched evolutionary pattern. The trunk alterations that existed throughout the course were restricted to IDH1
mutation, 1p/19q-codeletion, and TERT promoter mutation, and mutation of the known candidate tumor suppressor
genes CIC and FUBP1 were not consistently observed between primary and recurrent tumors. Multiple sampling from
different regions within a tumor showed marked intratumoral heterogeneity. Notably, in general, the number of
mutations was not significantly different after recurrence, remaining under 100, and no hypermutator phenotype was
observed. FUBP1 mutation, loss of chr. 9p21, and TCF12 mutation were among a few recurrent de novo alterations that
were found at recurrence, indicating that these events were clonally selected at recurrence but were not enough to
enhance malignancy. Genome-wide methylation status, measured by Illumina 450 K arrays, was stable between
recurrence and the primary tumor. In summary, although oligodendroglioma displays marked mutational heterogeneity,
histological malignant transformation accompanying events such as considerable increase in mutation number and
epigenetic profile change were not observed at recurrence, indicating that noticeable temporal and spatial genetic
heterogeneity in oligodendrogliomas does not result in rapid tumor progression.
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Introduction
The recently updated World Health Organization (WHO)
classification of central nervous system (CNS) neoplasms
incorporated molecular information into the definition of
some CNS tumors, thereby officially turning a page into
the era of molecular diagnosis of CNS neoplasms. Among
such neoplasms, oligodendroglioma was defined as
IDH-mutant and 1p/19q-codeleted, making the 1p/
19q-codeletion part of the definition of this tumor a quar-
ter of a century after it was first noticed in oligodendrogli-
oma [33]. This genetic alteration is caused by unbalanced
translocation of chromosome (chr.) 19p to 1q, leading to
the whole arm loss of 1p and 19q. Recent research using
next-generation sequencing analysis has revealed the
mutational landscape of lower-grade gliomas including
oligodendroglioma [13, 35]. Interestingly, the 1p/19q-
codeletion has tight positive association with IDH muta-
tions and TERT promoter mutations, while it is mutually
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exclusive with ATRX loss and TP53 mutation, which are
the hallmark of diffuse astrocytoma, IDH-mutant. Some
(30-60%) of 1p/19q-codeleted tumors also have accom-
panying mutations of CIC, FUBP1 or NOTCH1, but these
mutations do not appear to be essential for establishment
of the histological and clinical features of oligodendrogli-
omas [4]. Although it is still unknown how 1p/19q-codele-
tion contributes to the oncogenesis of oligodendroglioma,
this alteration is known to be clinically important because
tumors with 1p/19q-codeletion have shown remarkable
response to combined chemotherapy with procarbazine,
lomustine, and vincristine (PCV therapy) [11], which has
been confirmed in multiple clinical trials [8, 10, 37]. In
contrast to diffuse astrocytoma, IDH-mutants that often
undergo malignant progression [3, 20], oligodendroglioma
has longer progression free survival and a lower tendency
to progress to very aggressive tumors [22]. However, again,
the molecular mechanisms that underlie such behaviors
are not well known. To gain insight into the molecular
mechanism underlying this behavior of oligodendrogli-
oma, we investigated the genetic and epigenetic profile of
1p/19q-codeleted oligodendroglioma at recurrence and
compared them to those of the original tumor.
Materials and methods
Patients and samples
Tumor samples and paired normal blood samples were
obtained at Dokkyo Medical University Hospital, Tokyo
University Hospital, National Cancer Center Hospital,
and Kyorin University Hospital. Details of the patient
characteristics and clinical course are provided in
Additional file 1: Table S1. IDH1/2 mutation was exam-
ined by Sanger sequencing, and 1p/19q-codeletion was
examined using microsatellite analysis or multiplex
ligation-dependent probe amplification (MLPA) methods,
spanning the centromeric to telomeric loci to detect
the whole arm deletion as described previously [29, 30].
Histological diagnoses were made according to the
2016 WHO guidelines by an experienced neuropath-
ologist in each of the respective treatment centers
and were further reviewed by a senior neuropathologist (J.
S.). In the recently updated classification, all tumors should
be classified as oligodendroglioma or anaplastic oligo-
dendroglioma. This study was approved by the ethics
committees of each institute and written informed consent
was obtained from all patients.
DNA and RNA extraction
The AllPrep DNA/RNA Micro kit (Qiagen) was used to
extract DNA and RNA from fresh frozen tumor tissue,
following the manufacturer’s protocols. The QIAamp
DNA Mini Kit (Qiagen) was used to extract control gen-
omic DNA from the paired blood samples. The Qubit
Assay Kit (Thermo Fisher Scientific) was used to measure
the concentration of double-stranded DNA, and the 2100
Bioanalyzer system (Agilent Technologies) was used to
measure the quality of RNA. The RNA Integrity Number
(RIN) was > 7 in most of the RNA samples.
Exome sequencing
Whole exons were enriched using the SureSelect Human
All Exon Kit (Agilent) following the manufacturer’s pro-
tocols. The capture version is shown in Additional file 1:
Table S2. Sequencing was performed as 100-bp pair-
ended reads using the HiSeq2000 (Illumina).
Mutation identification
The Burrows-Wheeler Aligner (BWA) [27] and Novoa-
lign software (Novocraft Technologies) were used to
align next-generation sequencing (NGS) reads to the hu-
man reference genome GRCh37/hg19. After removal of
PCR duplicates, short-read micro re-aligner (SRMA) [18]
was used to improve variant discovery through local re-
alignments. To identify somatic mutations, we used an inte-
grated genotyper software (karkinos: http://sourceforge.net/
projects/karkinos/) that detects single nucleotide variants
(SNVs), copy number variation (CNV) and tumor purity
[21]. A heuristic algorithm was used for SNV detection as
previously reported [21, 36]. Somatic mutant allele frequen-
cies adjusted by estimated tumor content ratios that
were ≥15% were retained. Artifacts originating from errors
in the sequence and mapping were also filtered by heuristic
filtering and Fisher’s test. To eliminate germline variations
in this study, we carried out comparative analyses using
paired tumor and normal samples for each of the samples
analyzed and we extracted the somatic events detected
only in tumor tissues. Mutations were validated by Sanger
sequencing or by RNA sequencing.
TERT promoter mutation
Mutations within the TERT promoter regions were
detected by Sanger sequencing with previously re-
ported primers [23].
Copy number analysis
Read depths were compared between normal and tumor
for each capture target region. After normalizing by
number of total reads and GC content bias, the tumor/
normal depth ratio was calculated and values were
smoothed using a moving average. Copy number peaks
were then estimated using wavelet analysis, and each
peak was approximated using complex Gaussian models.
A hidden Markov model (HMM) and calculated Gaussian
models were constructed and copy number peaks were
linked to a genomic region. Allelic imbalance for each
copy number peak was then calculated, and imbalance in-
formation and peak distance were further analyzed by
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model fitting, yielding integer copy number annotation
and tumor purity [21].
RNA sequencing
An RNA sequencing library was prepared using the TruSeq
Stranded mRNA LT Sample Prep Kit (Illumina) according
to the manufacturer’s protocol. Briefly, 1 μg of total RNA
was purified using oligo dT magnetic beads and poly A+
RNA was fragmented by heating at 94 °C for 2 min. cDNA
was synthesized using SuperScript II (Invitrogen) and
adapter ligated cDNA was amplified using 12 cycles of
PCR. Each library was sequenced using HiSeq2000, in
which four libraries were loaded per lane of the flowcell,
producing an average of 28.7 million pairs of 101-cycle
reads for each sample.
NGS reads were independently mapped to a cDNA data-
base (UCSC genes) and a reference genome (GRCh37/
hg19) using the BWA. After a cDNA coordinate was con-
verted to genomic positions, the optimal mapping result
was chosen either from cDNA or genome mapping by
comparing the minimal edit distance to the reference. Sub-
sequently, local realignment was done with an in-house
short reads aligner with a small seed size (k = 11) (Qgram-
SmithWaterman).
Genome-wide methylation profiling
The Infinium assay was performed according to Illumina’s
standard protocol using the Infinium Human Methylation
450 K BeadChip (Illumina). For each CpG site, the β-value
was calculated by using the following equation: intensity of
the Methylated allele (M) / intensity of the Unmethylated
allele (U) + intensity of the Methylated allele (M) +100 [5].
This β-value, which ranged from 0 (unmethylated) to 1
(fully methylated), reflects the methylation level of the indi-
vidual CpG site represented by the probe.
We downloaded Infinium Human Methylation 450 K
BeadChip data of 289 lower-grade gliomas from The
Cancer Genome Atlas (TCGA) Data Portal (https://
tcga-data.nci.nih.gov/docs/publications/lgg_2015) and ana-
lyzed these data together with the data of our 30 samples.
The following filtering steps were used to select probes for
unsupervised clustering analysis. Probes targeting the X
and Y chromosomes, and probes associated with a single
nucleotide polymorphism (SNP) according to TCGA data,
[7, 13] were excluded. The standard deviation (SD) of β-
values for each probe was calculated and the top 8000
probes were selected.
Promoter methylation of the O6-methylguanine DNA
methyltransferase (MGMT) gene
We adopted the MGMT-STP27 model, using two Infinium
Human Methylation 450 K BeadChip probes cg12434587
and cg12981137 [2], to determine MGMT promoter
methylation status.
Results
Characteristics of oligodendroglioma cases
We sequenced 12 pairs of primary and recurrent 1p/
19q-codeleted tumors (Additional file 1: Table S1). Of
these tumors, 2 progressed from WHO grade II to grade
III histologically, 9 remained as the same grade (8 as
grade III, 1 as grade II), and 1 grade III tumors were
diagnosed as grade II at recurrence (Additional file 2:
Figure S1). Regarding the treatment of the primary tu-
mors, all but one patient was treated with chemotherapy;
3 patients were treated with temozolomide (TMZ), 7 pa-
tients with a combination of procarbazine, nimustine
(ACNU) and vincristine (PAV chemotherapy), and 1 pa-
tient with ACNU and vincristine. PAV chemotherapy is
commonly used in place of PCV chemotherapy because of
the unavailability of lomustine (CCNU) as an approved
drug in Japan. In this cohort, four to eight courses (average,
6.9 courses) of PAV therapy were administered. Each
course of PAV chemotherapy consisted of procarbazine (at
a dose of 100 mg on days 8 through 21), ACNU (at a dose
of 80 mg per square meter of body-surface area, adminis-
tered intravenously on day 1), and vincristine (at a dose of
1.4 mg per square meter administered intravenously on
days 1 and 29). The cycle length was 6-8 weeks. Drug dos-
age was reduced when a severe side effect was observed in
the prior course. In addition to chemotherapy, 2 patients
also received radiation therapy, and the one remaining
patient was treated with radiation therapy alone. The
diagnosis of recurrence and the subsequent decision to
proceed with resection were made when the emergence
of a gadolinium-enhanced lesion (3 cases) or a notice-
able enlargement of a FLAIR-high region (9 cases) was
observed on MRI. Methionine PET high uptake of the
recurrent lesion was also used as supportive data to
make a diagnosis of recurrence in 9 cases. These 12 pa-
tients were followed up for a median time of 52 months
after the second surgery, and 8 patients were still alive
at that time, indicating that most of the recurrent oligo-
dendrogliomas could still be controlled by the treat-
ment used (Additional file 1: Table S1).
In addition, to investigate intratumoral heterogeneity, in
4 cases we analyzed paired samples obtained from two dif-
ferent regions that showed different imaging features within
the tumor. The imaging study used to decide these regions
was 11C-methionine positron emission tomography (MET-
PET) in 3 cases, and Gd-enhanced MRI in 1 case. A com-
puterized navigation system was used to obtain the samples
from targeted lesions. Histological diagnosis of all paired
samples was determined independently based on the H/E-
stained slides made from the corresponding tissues
(Additional file 1: Table S1 and Additional file 2: Figure
S2). All 4 patients were still alive during follow-up ranging
from 42 – 54 (average 47) months after surgery. Only one
patient (patient 14) showed local tumor recurrence.
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Mutation analysis
We performed exome sequencing of 32 tumors and 16
matched normal blood samples. The sequencing data
are summarized in Additional file 1: Table S2. Sequen-
cing depths for tumors and normal blood samples were
112.8× and 105.5× on averages, respectively, meaning
that sufficient numbers of reads for mutant alleles could
be obtained. At a sequencing depth of more than X20,
95.2 ± 2.0% of the coding sequence was covered on aver-
age. The estimated tumor purity was 78.9 ± 17.8% (ran-
ging from 41.3 - 98.0%) on average. In total, we detected
1138 non-synonymous mutations in 32 oligodendrogli-
oma samples analyzed by exome sequencing. A list of
the mutations and detailed information are shown in
Additional file 1: Table S3. For validation, 100 mutations
were randomly selected from samples with matched
RNA sequencing data. Of these 100 mutations, 41 had
more than 10 reads in RNA sequencing, and at least 34
of 41 (83%) mutations were confirmed, indicating rea-
sonably high reliability of the exome sequencing. The
average number of non-synonymous mutations in 12
pairs of primary and recurrent tumors was 30 (10 to 76)
and 43 (16 to 87), respectively (Fig. 1). The retention
rate, i.e., the fraction of initial tumor mutations pre-
served in the recurrent tumor [24], was 33.3% on aver-
age (3.2 to 57.9), which demonstrated that mutational
similarity of primary and recurrent tumors was low in
general, but varied significantly among the cases. Hyper-
mutated tumors, which have been reported in recur-
rence of glioblastomas and astrocytomas [12, 20] were
not found in the present recurrent oligodendrogliomas,
even after 12 courses of TMZ chemotherapy. Two cases
that demonstrated progression at recurrence had the
lowest retention rates of 3.2% (patient 4) and 12.5% (pa-
tient 2). A different mutation in the same gene was ob-
served in primary and recurrent tumors that involved
CIC in patient 2 and PIK3CA in patient 3, which dem-
onstrated a convergent evolution pattern. To deduce the
degree of advantage provided by each mutation for
tumor growth, we focused on mutations that were
retained or acquired in recurrent tumors. In some cases,
even well-known presumptive major driver mutations of
CIC, TP53 and PIK3CA that were detected in primary
tumors were not detected at recurrence (mutations in
CIC in patient 1, 5, 9 and 10; in TP53 in patient 10; and
in PIK3CA in patient 8). FUBP1 mutation was seen in
six out of the twelve recurrent tumors; such mutation
was acquired in recurrent tumors in 2 cases (patients 2
and 11), and the same FUBP1 mutation as that in the
primary tumor was retained in the recurrent tumor in 4
cases (patients 5, 8, 10, and 12). There was no case in
which FUBP1 mutation was lost at recurrence. TCF12
mutation was acquired in two out of the twelve recur-
rent tumors (patients 1 and 4).
Copy number aberrations
Chromosome 1p/19q-codeletion was retained in all re-
current tumors. Frequent copy number alteration (CNA)
was observed at the 9p21 locus containing the CDKN2A
gene, where allelic loss or uniparental disomy (UPD) was
observed in 8 cases. In our series, an increase in gen-
omic instability was not typical at recurrence and some
recurrent tumors even demonstrated decreased genomic
aberrations compared to those of the respective primary
tumors. For example, in patient 3 (Fig. 2), the primary
tumor was anaplastic oligodendroglioma and, after 12
courses of TMZ chemotherapy, the tumor recurred
along the margin of the resection cavity. The recurrent
tumor showed noticeable enlargement of a high intensity
region on MRI fluid-attenuated inversion recovery
(FLAIR) image with high uptake by MET-PET, and was
surgically resected. The pathological diagnosis was still
anaplastic oligodendroglioma; however, tumor cells were
sparse, atypia of the nucleus was slightly improved, and
the number of mitotic cells was decreased in the recurrent
tumor compared to the primary tumor. Both the primary
and the recurrent tumors had mutations in IDH1 and the
TERT promoter as well as 1p/19q-codeletion. PIK3CA
mutations were also commonly found, although the
mutated position in the gene was different between the re-
current and the primary tumor, indicating that convergent
evolution had occurred in the course of tumor growth.
CIC mutation was found only in the recurrent tumor. In
that case, chromosomal instability, which may be related
to the formation of malignancy, was evident only in the
primary tumor. This patient is still healthy 76 month after
the second surgery.
Intratumoral heterogeneity
In four cases, we were able to analyze multiple samples
obtained from different tumor regions, where a difference
in methionine uptake on MET-PET or in enhancement by
gadolinium on MRI was observed preoperatively in the
same tumor. The rate of shared mutation was 43.1% on
average (9.5 - 63.6%). Similar to the analysis comparing
primary and recurrent tumors, the mutation status dif-
fered among tumor regions, even that of major driver
genes such as CIC, FUBP1, PTEN, and NOTCH1 (Fig. 3).
IDH1 mutations were identical in both tumor regions in
all 4 cases. Of note, however, different TERT promoter
mutation status between regions was observed in two
samples; in case 14, one Gd non-enhancing portion had a
C228T mutation and the other enhancing portion had a
C250T mutation; in patient 15, only the histologically
progressive portion had a C228T mutation (Fig. 4). CIC
mutations were identified in all 4 tumor regions with high
methionine uptake or enhancement, while no CIC muta-
tion was found in regions with low methionine uptake or
no Gd enhancement. In copy number analysis, 2 cases
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showed a difference in 9p status, and 2 cases showed a
difference in chr. 15 status between regions, while the
1p/19q-codeletion was present in all tumor regions.
Methylation analysis
We performed unsupervised clustering with 319 sam-
ples, which were comprised of the 30 oligodendrogli-
omas of the present study and 289 lower-grade gliomas
from TCGA (Fig. 5). Except for three cases, of which
two seemed to have a low tumor content in one of the
pair, paired samples were clustered next to each other,
and robust methylation change at recurrence or in dif-
ferent regions within each tumor was not observed; i.e.,
when primary 1p/19q-codeleted tumors were in the
cluster with higher methylation, the recurrent tumors
stayed in the same cluster. When primary tumors were
in the less methylated cluster, recurrent tumors also
stayed in the same cluster.
The MGMT promoter region was methylated in all tu-
mors (Figs. 1 and 3), indicating that MGMT promoter
methylation had not changed at recurrence or in differ-
ent regions within the same tumor.
Discussion
In the present study, similar to the results of previous
studies of astrocytic tumors [3, 20, 35], the mutation
Fig. 1 Summary of the genomic profiles of the primary and recurrent oligodendrogliomas. The number of non-synonymous mutations, WHO grade,
postoperative treatment, MGMT promoter methylation status, mutation profiles and copy number alterations are shown from top to bottom of the
panel. On the right of the panel, the percentage of retained and acquired mutations and copy number alterations are depicted
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retention rate at recurrence in oligodendrogliomas was
relatively low. In ten out of the twelve tumors, more
than half of the mutations found in the primary tumor
were not found in the recurrent tumor. These observa-
tions indicated that oligodendrogliomas show a complex
branched evolutionary pattern at recurrence similar to
other malignant gliomas. Indeed, in some recurrent tu-
mors, mutations such as CIC, TP53, and PIK3CA muta-
tions that are generally regarded as potent drivers were
not maintained at recurrence. On the other hand, muta-
tions in FUBP1, which is a transcriptional modulator of
c-MYC [19], were maintained or newly acquired at re-
currence, suggesting that these FUBP1 mutations may
confer a survival advantage. Similarly, although less fre-
quently, inactivating TCF12 mutations were acquired in
2 recurrent tumors; these mutations were frameshift
indels, p.97_97del in patient 1 and p.I162fs in patient 4.
Mutations leading to truncation of a basic helix-loop-
helix (bHLH) domain of the transcription factor TCF12
were previously detected in an aggressive type of 1p/
19q-codeleted tumor [26]. Those results, together with
our data, mean that such truncation can be considered
as one of the driving genetic alterations in recurrent
oligodendroglioma. Regarding copy number alterations,
apart from 1p/19q-codeletion, the 9p21 locus containing
the CDKN2A gene was the most frequently altered
locus. Alteration of this locus was not so frequent in 1p/
19q-codeleted tumors in previous large scale analyses
[13, 35]. However, alteration of the 9p21 locus was pre-
viously reported to be associated with histological
Fig. 2 An example of histopathological and molecular genetic alterations in recurrent anaplastic oligodendroglioma (Patient 3). The patient with
anaplastic oligodendroglioma was treated with 12 courses of temozolomide after gross total removal of the tumor, and MRI and 11C-Methionine –PET
detected regrowth of the tumor 17 months after this treatment. Histological analysis was anaplastic oligodendroglioma at recurrence, which showed
decreased tumor cell density, slight improvement of atypia of the nucleus, and decreased number of mitotic cells compared to the primary tumor.
Hemizygous loss of multiple foci was not preserved at recurrence, except for 1p/19q-codeletion. Clinical course, MRI and MET-PET images, pathological
images (H&E stained formalin-fixed paraffin-embedded tissue slides), copy number alterations and phylogenetic tree of the primary and recurrent
tumor are depicted from top to bottom of the panel
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malignancy such as microvascular proliferation and ne-
crosis [6, 15], as well as worse prognosis in 1p/19q-code-
leted tumors [1]. Even though the alterations described
above might have been clonally selected at recurrence
and were potentially associated with tumor growth, there
was no increase in malignant histological characteristics
in most of the recurrent tumors, and most of such tu-
mors could still be controlled by the treatment, demon-
strating that these events were not sufficient to enhance
tumor malignancy.
The rise of a hypermutator phenotype after TMZ
chemotherapy against low-grade gliomas has been re-
ported, raising some concern regarding the management
strategy for this tumor [20]. In our series of 12 pairs of pri-
mary and recurrent tumors, in which PAV chemotherapy
was used in the majority (7/12), neither a significant in-
crease in mutation number in recurrent tumors nor a
hypermutator phenotype was observed. One possible rea-
son for the absence of hypermutation in our series is that
astrocytic tumors with IDH mutation may be more prone
to a hypermutator phenotype compared to oligodendrogli-
omas, since a previous report demonstrated that a hyper-
mutator phenotype is frequently found in astrocytic
tumors harboring IDH mutation that were treated with
TMZ [20, 24]. It has also been reported that a hypermuta-
tor phenotype might be infrequent in glioblastoma
Fig. 3 Summary of genomic profiles in different regions of oligodendrogliomas. Mutation and copy number analysis of samples in different
regions of the tumor in four patients. The number of non-synonymous mutations, clinical grade, MGMT promoter methylation status, mutation
profiles and copy number alterations are shown from top to bottom of the panel. On the right of the panel, the percentage of retained and
acquired mutations and copy number alterations are depicted
Aihara et al. Acta Neuropathologica Communications  (2017) 5:18 Page 7 of 11
without IDH mutation, suggesting that the incidence rate
of the hypermutator phenotype is different among glioma
subtypes [24]. Another possible explanation is that only
three cases were treated with TMZ, which is thought to
be a major driver for the hypermutator phenotype, and
that PAV therapy, which is an analogous regimen to PCV
chemotherapy in Japan, is less likely to cause a hypermuta-
tor phenotype. The emergence of a hypermutator pheno-
type is thought to be related to the mechanism of action
of TMZ, and to chemical reactions of alkylating agents be-
longing to the triazene group such as TMZ, procarbazine,
and dacarbazine, which differ from those of nitrosoureas
such as ACNU, BCNU, and CCNU. Briefly, TMZ adds a
methyl group to the O6 position of a guanine residue to
make O6-methylguanine, which leads to the addition of a
thymine residue instead of a cytosine into the paired DNA
strand when DNA replicates. These mismatch residues
are recognized by the mismatch repair system. An attempt
to repair this mismatch is then initiated, which cannot be
completed in the presence of O6-methylguanine and
therefore the process ends up with thymine reinsertion,
leading to a futile mismatch repair cycle and eventually
apoptosis [16, 32]. A defect in the mismatch repair system
confers resistance to TMZ but leads to a large amount of
C > T/G >A mutations [12, 20]. On the other hand, nitro-
soureas such as ACNU add a chloroethyl group to the O6
position of a guanine residue, making O6-chloroethylgua-
nine, and subsequent cross-linking prevents DNA replica-
tion and induces apoptosis [34]. Thus, the mechanism of
action of ACNU is not related to the mismatch repair sys-
tem, and therefore these drugs will not cause a hypermu-
tator phenotype. Although procarbazine that is used in
PAV chemotherapy has a similar pharmacological action
to TMZ, the dosage and duration of procarbazine treat-
ment are different from those of TMZ and such differ-
ences might affect the incidence rate of a hypermutator
phenotype. Indeed, there did not seem to be a frequent
rise in a hypermutator phenotype after chemotherapy that
consisted mainly of nitrosourea in our oligodendroglioma
cases. A recent phase III study showed that radiation plus
PCV chemotherapy elongates progression-free survival and
overall survival of high-risk low-grade glioma, especially of
oligodendroglioma [8]. Although TMZ is a candidate sub-
stitute for PCV therapy, which often results in relatively se-
vere side effects, it may be necessary to consider such
possible different consequences of these regimens and to
investigate genomic status in a larger series of recurrent gli-
omas in the future. Understanding those molecular dy-
namic features might be essential for planning of the future
treatment strategy, including molecular targeting therapy,
for sufficient control of this tumor.
Recent studies using whole-exome sequencing have re-
vealed that lower-grade gliomas also harbor intratumoral
heterogeneity, which is widely observed in malignant tu-
mors such as glioblastomas [17, 25, 35]. We observed
here that oligodendroglioma, which generally has a bet-
ter prognosis compared with astrocytic tumors, also
demonstrates marked intratumoral heterogeneity. Mu-
tant allele frequencies were generally low; < 0.75, < 0.5,
and < 0.25 in 96%, 87%, and 42% of the number of iden-
tified gene mutations, respectively, which most likely re-
flect heterogeneity within the tumor. Among genetic
and chromosomal alterations, IDH1 mutation and 1p/
19q-codeletion were prevalent in almost all tumor cells
and are considered to be the trunk alterations. However,
in two analyzed cases, analysis of regions that showed
different histological and imaging features within a
tumor demonstrated that TERT promoter mutation was
not identical in these regions. Previous reports also dem-
onstrated slightly less than 100% incidence of TERT pro-
moter mutation in 1p/19q-codeleted oligodendrogliomas
[13, 35]. In addition, the presence of other mutations
Fig. 4 Representative cases illustrating intratumoral heterogeneity. a
In patient 14, the Gd-enhanced tumor center and the marginal
non-enhanced part of the tumor were separately collected. The TERT
promoter mutation was different in each tumor region. b In patient 15,
the tumor center with MET-PET high uptake, and the marginal tumor
portion with MET-PET low uptake, were separately collected. Only the
tissue with MET-PET high uptake had TERT promoter mutation
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that are frequently observed in oligodendrogliomas can
vary temporally and spatially within a tumor. Therefore,
mutations other than IDH1 and 1p/19q-codeletion in-
cluding TERT promoter mutation appear to be later
events in oligodendroglioma oncogenesis.
The combined data presented here suggest interesting
genetic features of oligodendrogliomas. The number of
mutations harbored by oligodendroglioma is not neces-
sarily smaller than that reported for astrocytic tumors,
and there appears to be marked intratumoral heterogen-
eity. Although tumor heterogeneity is often related to
the malignant nature of tumors, in recurrent oligo-
dendrogliomas there was no tendency for mutation in-
crease at recurrence, and, in some cases, there were
fewer mutations and copy number aberrations at recur-
rence than in the primary tumor. In addition to such ob-
servations of genetic and genomic changes, minimal
epigenetic changes were observed in recurrent oligo-
dendroglioma compared to the primary tumor. Such epi-
genetic stability is in contrast to that of astrocytic
tumors that harbor IDH mutation, which demonstrate a
dynamic methylation profile change during malignant
progression [14, 28]. In our series, MGMT promoter
methylation was also stable among tissues from the
same patient, although a previous study suggested that
there is clonal heterogeneity of MGMT promoter methy-
lation even in oligodendroglioma [31].
Conclusions
Although oligodendroglioma display remarkable spatial
and temporal heterogeneity that is known to be related to
tumor evolution [9], our study demonstrated that their
tumor malignancies are rarely promoted by additionally
acquired mutations or genomic aberrations at recurrence.
Such molecular characteristics may account for clinically
benign nature of oligodendroglioma compared to other
diffuse gliomas, and may influence tailored therapeutic
strategy for this tumor in the future.
Additional files
Additional file 1: Table S1. Clinical characteristics of the patient cohort.
Table S2. Sequence data summary. Table S3. List of the somatic
mutations in this study. (XLSX 163 kb)
Additional file 2: Figure S1. Histopathological features of primary and
recurrent tumors in a 34 year-old female (patient 6). The primary tumor
was diagnosed as anaplastic oligodendroglioma (WHO grade III) (A).
Postoperatively, the patient was treated with 8 courses of PAV chemotherapy.
Eight years after the initial surgery, an MRI FLAIR-high lesion was noticeably
enlarged and this region showed high uptake in Methionine PET. Tumor
recurrence was therefore suspected and surgical resection was performed. In
Fig. 5 Genome-wide methylation status was stable between recurrence and the primary tumor. Heatmap of the methylation levels (β-value) in
319 samples, including the 30 oligodendrogliomas of the present study and 289 lower-grade gliomas from TCGA. Unsupervised clustering was
performed using 8000 selected Infinium probes. Each row represents a probe, and each column represents one sample. For each sample, IDH1
mutation and 1p/19q-codeletion status are indicated by colored boxes at the bottom of the map. Samples connected with a line are pairs of
primary and recurrent tumors or samples in different regions of the tumor
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the recurrent tumor, atypia of the nucleus was improved and numbers of
mitotic cells were decreased compared to the primary tumor, and the tumor
was diagnosed as oligodendroglioma (WHO grade II) (B). Formalin-fixed
paraffin-embedded tissues were sectioned and stained with Hematoxylin and
Eosin (bar = 100 μm). Figure S2. Histopathological features of different tumor
portions from the same patient as listed in Additional file 1: Table S1.
Formalin-fixed paraffin-embedded tissues were sectioned and stained with
Hematoxylin and Eosin (bar = 100 μm). A. Patient 13, Methionine PET low
uptake, grade II; B. Patient 13, Methionine PET high uptake, grade III; C.
Patient 14, Gadolinium enhanced -, grade II; D. Patient 14, Gadolinium
enhanced +, grade III; E. Patient 15, Methionine PET low uptake, grade II; F.
Patient 15, Methionine PET high uptake, grade II; G. Patient 16, Methionine
PET low uptake, grade III; H. Patient 16, Methionine PET high uptake, grade III.
(PPTX 1597 kb)
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